2024
Four targets: an enhanced framework for guiding causal inference from observational data
Lu H, Li F, Lesko C, Fink D, Rudolph K, Harhay M, Rentsch C, Fiellin D, Gonsalves G. Four targets: an enhanced framework for guiding causal inference from observational data. International Journal Of Epidemiology 2024, 54: dyaf003. PMID: 39868475, PMCID: PMC11769716, DOI: 10.1093/ije/dyaf003.Peer-Reviewed Original Research
2023
ASAM Clinical Considerations: Buprenorphine Treatment of Opioid Use Disorder for Individuals Using High-potency Synthetic Opioids
Weimer M, Herring A, Kawasaki S, Meyer M, Kleykamp B, Ramsey K. ASAM Clinical Considerations: Buprenorphine Treatment of Opioid Use Disorder for Individuals Using High-potency Synthetic Opioids. Journal Of Addiction Medicine 2023, 17: 632-639. PMID: 37934520, DOI: 10.1097/adm.0000000000001202.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHigh potency synthetic opioidsOpioid use disorderBuprenorphine initiationBuprenorphine treatmentTreatment needsUse disordersClinical considerationsExpert consensusSynthetic opioidsTreatment of OUDProspective researchOpioid agonist treatmentLong-term treatmentDrug supplyPatients' treatment needsOpioid withdrawalBuprenorphine doseOUD treatmentAgonist treatmentDosing frequencyClinical questionsFrontline cliniciansClinical practiceTreatment settingsIndividualized strategies
2022
Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community
Biondi BE, Vander Wyk B, Schlossberg EF, Shaw A, Springer SA. Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community. Addiction Science & Clinical Practice 2022, 17: 15. PMID: 35255967, PMCID: PMC8899775, DOI: 10.1186/s13722-022-00299-1.Peer-Reviewed Original ResearchConceptsOpioid use disorderHigher pain interferenceMOUD retentionPain interferenceUse disordersOngoing prospective cohort studySevere opioid use disorderProspective cohort studyMultivariable logistic regressionCohort of adultsMethadone doseAnalgesic effectBuprenorphine doseCohort studyOpioid useResultsA totalHigher oddsMOUDAdjusted modelHigh doseLogistic regressionBuprenorphineMethadoneDoseDiscontinuation
2021
Low Dose Initiation of Buprenorphine: A Narrative Review and Practical Approach
Cohen SM, Weimer MB, Levander XA, Peckham AM, Tetrault JM, Morford KL. Low Dose Initiation of Buprenorphine: A Narrative Review and Practical Approach. Journal Of Addiction Medicine 2021, 16: 399-406. PMID: 34954746, DOI: 10.1097/adm.0000000000000945.Peer-Reviewed Original ResearchConceptsLow dose initiationFull opioid agonistsDose initiationOpioid withdrawal symptomsOpioid agonistsBuprenorphine doseWithdrawal symptomsHigh potency synthetic opioidsOpioid use disorderAppropriate clinical situationsMu-opioid receptorsBuprenorphine initiationOpioid withdrawalStarting doseOutpatient settingCare coordinationDose changesOverdose deathsCurrent evidenceUse disordersBuprenorphineTherapeutic levelsClinical situationsSynthetic opioidsNarrative reviewHigh-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder
Herring AA, Vosooghi AA, Luftig J, Anderson ES, Zhao X, Dziura J, Hawk KF, McCormack RP, Saxon A, D’Onofrio G. High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder. JAMA Network Open 2021, 4: e2117128. PMID: 34264326, PMCID: PMC8283555, DOI: 10.1001/jamanetworkopen.2021.17128.Peer-Reviewed Original ResearchConceptsOpioid use disorderEmergency departmentBuprenorphine inductionRespiratory depressionAdverse eventsUse disordersUntreated opioid use disorderSerious adverse eventsFurther prospective investigationLength of stayUrban emergency departmentSafety-net hospitalAdvanced practice practitionersElectronic health recordsUnique cliniciansSublingual buprenorphineBuprenorphine doseED visitsED encountersCase seriesED patientsED physiciansSupplemental oxygenMedian lengthUnique patients
2011
Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients
McCance-Katz EF, Moody DE, Prathikanti S, Friedland G, Rainey PM. Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients. Drug And Alcohol Dependence 2011, 118: 326-334. PMID: 21596492, PMCID: PMC3272858, DOI: 10.1016/j.drugalcdep.2011.04.013.Peer-Reviewed Original ResearchConceptsBuprenorphine plasma concentrationsWithdrawal symptomsOpiate withdrawalPlasma concentrationsBuprenorphine-maintained patientsBuprenorphine-maintained subjectsDays of rifampinOpioid partial agonistBuprenorphine/naloxoneFirst-line treatmentOpiate withdrawal symptomsSignificant adverse eventsActive metabolite concentrationsOpioid-dependent individualsPlasma buprenorphine concentrationsBuprenorphine pharmacokineticsStable dosesAdverse eventsBuprenorphine doseBuprenorphine therapyAntituberculosis medicationPharmacodynamic interactionsRifampin administrationOpioid dependenceLine treatment
2007
Interaction between buprenorphine and atazanavir or atazanavir/ritonavir
McCance-Katz EF, Moody DE, Morse GD, Ma Q, DiFrancesco R, Friedland G, Pade P, Rainey PM. Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug And Alcohol Dependence 2007, 91: 269-278. PMID: 17643869, PMCID: PMC3272856, DOI: 10.1016/j.drugalcdep.2007.06.007.Peer-Reviewed Original ResearchConceptsAtazanavir/ritonavirDrug interactionsMini-Mental State ExaminationOpioid partial agonistPharmacokinetics of atazanavirPharmacokinetics of buprenorphineHIV-negative volunteersEffects of buprenorphineConcentrations of buprenorphineAdverse drug interactionsProtease inhibitor atazanavirAntiretroviral administrationBuprenorphine doseHIV diseaseBuprenorphine treatmentHIV medicationsBuprenorphine/Opioid dependencePharmacodynamic effectsRitonavir concentrationsHealthy controlsOpioid addictionBuprenorphineState ExaminationAtazanavir
2005
Buprenorphine tablet versus liquid: A clinical trial comparing plasma levels, efficacy, and symptoms
Chawarski MC, Moody DE, Pakes J, O'Connor PG, Schottenfeld RS. Buprenorphine tablet versus liquid: A clinical trial comparing plasma levels, efficacy, and symptoms. Journal Of Substance Use And Addiction Treatment 2005, 29: 307-312. PMID: 16311183, DOI: 10.1016/j.jsat.2005.08.011.Peer-Reviewed Original ResearchConceptsTrough concentrationsPlasma concentrationsOpiate-dependent volunteersIllicit opioid usePeak plasma concentrationBuprenorphine doseBuprenorphine tabletsOpioid useWithdrawal symptomsBuprenorphine levelsPlasma levelsTablet doseClinical trialsLarge intersubjectLiquid formulationStudy participantsIntrasubject variabilityPlasma samplesPeak concentrationTablet formulationLiquid dosesDays of maintenanceSymptomsDoseConcentration curve
1999
Plasma concentrations of buprenorphine 24 to 72 hours after dosing
Chawarski MC, Schottenfeld RS, O’Connor P, Pakes J. Plasma concentrations of buprenorphine 24 to 72 hours after dosing. Drug And Alcohol Dependence 1999, 55: 157-163. PMID: 10402160, DOI: 10.1016/s0376-8716(98)00192-6.Peer-Reviewed Original ResearchConceptsDose scheduleWithdrawal symptomsPlasma concentrationsDaily buprenorphine doseHigh-dose scheduleThrice-weekly scheduleAdministration of buprenorphineOpiate-dependent subjectsHigher plasma concentrationsUse of heroinBuprenorphine doseDaily administrationOutpatient clinicPlasma levelsSublingual administrationAgonist effectsOpiate useHeroin useLow doseHigh doseBuprenorphine solutionMg/70High dosesConcentration 24Dependent subjects
1994
Buprenorphine: duration of blockade of effects of intramuscular hydromorphone
Rosen M, Wallace E, McMahon T, Pearsall H, Woods S, Price L, Kosten T. Buprenorphine: duration of blockade of effects of intramuscular hydromorphone. Drug And Alcohol Dependence 1994, 35: 141-149. PMID: 7519977, DOI: 10.1016/0376-8716(94)90121-x.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply